Previous Close | 54.50 |
Open | 55.32 |
Bid | 52.99 x 1000 |
Ask | 56.75 x 800 |
Day's Range | 53.31 - 55.58 |
52 Week Range | 50.38 - 72.72 |
Volume | |
Avg. Volume | 1,162,863 |
Market Cap | 6.18B |
Beta (5Y Monthly) | 1.97 |
PE Ratio (TTM) | 14.36 |
EPS (TTM) | 3.83 |
Earnings Date | Apr 25, 2022 - Apr 29, 2022 |
Forward Dividend & Yield | 0.60 (1.06%) |
Ex-Dividend Date | Mar 14, 2022 |
1y Target Est | 79.64 |
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
- $209.7 Million Cash and Cash Equivalents at March 31, 2022 – - Over 120 Patients Now Enrolled in Phase 3 Program - AUSTIN, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the first quarter ended March 31, 2022 and provided a clinical update on its Phase 3 clinical program of simufilam in Alzheimer’s disease. Simufilam is Cassava Sciences’ lead drug candida
Boyd Gaming Corporation ( NYSE:BYD ), is not the largest company out there, but it received a lot of attention from a...